Literature DB >> 8409332

MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis.

X Chenivesse1, D Franco, C Bréchot.   

Abstract

MDR1 RNA levels were analysed in patients with hepatocellular carcinoma (HCC), benign liver tumors or cirrhosis. None of the patients with HCC had received chemotherapy. MDR1 RNA levels were increased relative to a normal liver specimen in 15/26 liver cancers, 2/6 benign liver tumors and 0/8 tumor-free cirrhotic livers. MDR1 was also overexpressed in cirrhotic non-tumorous liver tissues of some patients with HCC. The results indicate that the MDR1 gene is overexpressed in liver tumors and some preneoplastic lesions and that might account for the very poor response of primary liver cancers to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8409332     DOI: 10.1016/s0168-8278(05)80243-0

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

1.  Nanodiamond delivery circumvents tumor resistance to doxorubicin.

Authors:  Xiao-wei Ma; Yu-liang Zhao; Xing-jie Liang
Journal:  Acta Pharmacol Sin       Date:  2011-05-02       Impact factor: 6.150

Review 2.  The biology of the P-glycoproteins.

Authors:  C R Leveille-Webster; I M Arias
Journal:  J Membr Biol       Date:  1995-01       Impact factor: 1.843

Review 3.  Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful?

Authors:  Natale D'Alessandro; Paola Poma; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

4.  Treatment of hepatocellular carcinoma: considerations regarding etiology and molecular biology.

Authors:  Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2007

5.  Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.

Authors:  Se Hoon Park; Yuna Lee; Sang Hoon Han; So Young Kwon; Oh Sang Kwon; Sun Suk Kim; Ju Hyun Kim; Yeon Ho Park; Jeong Nam Lee; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  BMC Cancer       Date:  2006-01-05       Impact factor: 4.430

6.  Thalidomide for treating metastatic hepatocellular carcinoma: a pilot study.

Authors:  Sang Hoon Han; Se Hoon Park; Jung Ho Kim; Jong Jun Lee; So Young Kwon; Oh Sang Kwon; Sun Suk Kim; Ju Hyun Kim; Keon Kug Kim; Yeon Ho Park; Jeong Nam Lee; Eunmi Nam; Soo-Mee Bang; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Korean J Intern Med       Date:  2006-12       Impact factor: 2.884

Review 7.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31

8.  Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.

Authors:  Neeta K Venepalli; Laura Goff
Journal:  Int J Hepatol       Date:  2013-03-31

9.  Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR.

Authors:  Vito R Cicinnati; Qingli Shen; Georgios C Sotiropoulos; Arnold Radtke; Guido Gerken; Susanne Beckebaum
Journal:  BMC Cancer       Date:  2008-11-27       Impact factor: 4.430

Review 10.  Plasma membrane transporters in modern liver pharmacology.

Authors:  Jose J G Marin
Journal:  Scientifica (Cairo)       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.